Insider · CIK 0001725663

WENTWORTH KORY JAMES

Reports to the SEC for 2 companies · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001725663

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-02	TRDAEntrada Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−1,733 sh	$7.14	−$12.4K	117,277
2026-04-01	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,500 sh	$12.95	−$32.4K	119,010
2026-03-10	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−11.4K sh	$13.02	−$148K	121,510
2026-03-09	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−5,089 sh	$13.00	−$66.2K	132,898
2026-03-04	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−7,988 sh	$12.25	−$97.9K	137,987
2026-03-03	TRDAEntrada Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−5,712 sh	$11.76	−$67.2K	145,975
2026-03-02	TRDAEntrada Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−2,939 sh	$11.66	−$34.3K	151,687
2026-03-01	TRDAEntrada Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+44.6K sh	—	—	154,626
2026-03-01	TRDAEntrada Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+66.6K sh	—	—	66,600
2025-11-21	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−8,910 sh	$9.98	−$88.9K	110,026
2025-09-02	TRDAEntrada Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−1,734 sh	$5.43	−$9,415.967	118,936
2025-04-03	TRDAEntrada Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+11.1K sh	$2.10	+$23.4K	120,670
2025-04-03	TRDAEntrada Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−11.1K sh	—	—	20,023
2025-03-17	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,784 sh	$10.67	−$19K	109,536
2025-03-03	TRDAEntrada Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−4,929 sh	$11.68	−$57.6K	111,320
2025-03-01	TRDAEntrada Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+42.4K sh	—	—	116,249
2025-03-01	TRDAEntrada Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+63.3K sh	—	—	63,300
2024-12-02	TRDAEntrada Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,000 sh	$2.10	+$10.5K	78,849
2024-12-02	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−5,000 sh	$20.00	−$100K	73,849
2024-12-02	TRDAEntrada Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,000 sh	—	—	31,157
2024-11-29	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,000 sh	$19.97	−$20K	73,849
2024-11-29	TRDAEntrada Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+1,000 sh	$2.10	+$2,100	74,849
2024-11-29	TRDAEntrada Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−1,000 sh	—	—	36,157
2024-11-11	TRDAEntrada Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+6,000 sh	$2.10	+$12.6K	82,486
2024-11-11	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−8,637 sh	$19.98	−$173K	73,849
2024-11-11	TRDAEntrada Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,000 sh	—	—	37,157
2024-09-09	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,195 sh	$14.97	−$47.8K	76,486
2024-09-05	TRDAEntrada Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−165 sh	$15.13	−$2,495.79	79,681
2024-09-04	TRDAEntrada Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−941 sh	$15.42	−$14.5K	79,846
2024-09-03	TRDAEntrada Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−462 sh	$15.76	−$7,281.628	80,950
2024-09-03	TRDAEntrada Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−149 sh	$16.93	−$2,521.9	80,801
2024-09-03	TRDAEntrada Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−14 sh	$17.70	−$247.828	80,787
2024-07-08	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,758 sh	$14.95	−$26.3K	81,412
2024-03-15	TRDAEntrada Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+9,000 sh	$2.10	+$18.9K	83,170
2024-03-15	TRDAEntrada Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−9,000 sh	—	—	43,157
2024-03-06	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−4,086 sh	$12.31	−$50.3K	74,170
2024-03-05	TRDAEntrada Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−1,471 sh	$12.28	−$18.1K	78,256
2024-03-04	TRDAEntrada Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−339 sh	$12.42	−$4,211.397	80,132
2024-03-04	TRDAEntrada Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−405 sh	$13.37	−$5,413.757	79,727
2024-03-01	TRDAEntrada Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+30.9K sh	—	—	80,471
2024-03-01	TRDAEntrada Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+46.8K sh	—	—	46,800
2023-12-26	TRDAEntrada Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+94 sh	$2.10	+$197.4	49,665
2023-12-26	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−94 sh	$16.67	−$1,566.98	49,571
2023-12-26	TRDAEntrada Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−94 sh	—	—	52,157
2023-12-22	TRDAEntrada Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+10.2K sh	$2.10	+$21.4K	59,777
2023-12-22	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−6,529 sh	$15.24	−$99.5K	53,248
2023-12-22	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,677 sh	$16.48	−$60.6K	49,571
2023-12-22	TRDAEntrada Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−10.2K sh	—	—	52,251
2023-12-21	TRDAEntrada Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,200 sh	$2.10	+$4,620	51,771
2023-12-21	TRDAEntrada Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,200 sh	$15.07	−$33.2K	49,571

Recent filings

Accepted (ET)
Sep 34
WENTWORTH KORY JAMES0001725663-26-000007
SEC(opens sec.gov)
Apr 24
WENTWORTH KORY JAMES0001725663-26-000005
SEC(opens sec.gov)
Mar 114
WENTWORTH KORY JAMES0001725663-26-000003
SEC(opens sec.gov)
Mar 64
WENTWORTH KORY JAMES0001725663-26-000002
SEC(opens sec.gov)
Mar 34
WENTWORTH KORY JAMES0001725663-26-000001
SEC(opens sec.gov)
Nov 244
WENTWORTH KORY JAMES0001725663-25-000004
SEC(opens sec.gov)
Sep 44
WENTWORTH KORY JAMES0001725663-25-000003
SEC(opens sec.gov)
Apr 44
WENTWORTH KORY JAMES0001689375-25-000019
SEC(opens sec.gov)
Mar 194
WENTWORTH KORY JAMES0001689375-25-000016
SEC(opens sec.gov)
Mar 44
WENTWORTH KORY JAMES0001689375-25-000014
SEC(opens sec.gov)
Dec 34
WENTWORTH KORY JAMES0001689375-24-000068
SEC(opens sec.gov)

Companies

Address

C/O ENTRADA THERAPEUTICS, INC. ONE DESIGN CENTER PLACE, SUITE 17-500

BOSTON, MA, 02210